BIO 2027 is the upcoming Biotechnology Innovation Organization event held in Philadelphia, aimed at professionals in the biotech industry. It offers networking opportunities and showcases the latest advancements in biotechnology.
BIO 2027 in Philadelphia offers an extensive program designed to connect biotech professionals with cutting-edge innovations and opportunities. Expect a diverse range of sessions, from keynote presentations by global biotech leaders to interactive workshops focusing on skill enhancement. Attendees will explore themes such as drug development, biotechnology commercialization, and the latest regulatory updates. This event is pivotal for professionals looking to expand their network and deepen their understanding of the biotech landscape.
What you will learn
Cutting-edge biotechnology innovations and trends
Strategies for drug development and commercialization
Networking with leading biotech professionals
Partnership opportunities in the biotech sector
Regulatory challenges and solutions in biotechnology
Want to exhibit at this event?
MarketScale can act as a third-party concierge, helping you request exhibitor packages, pricing, and booth availability. No cold calls, no commitment.
Key Highlights
• Keynote speeches from industry leaders
• Focused sessions on biotechnology advancements
• In-depth panel discussions
• Workshops for skill development
• Exhibits from leading biotech companies
Frequently asked questions
Topics & tracks
MarketScale platform
Exhibiting at this event?
Capture customer testimonials onsite, with your iPhone.
MarketScale turns every booth conversation into a produced video clip, written article, and social posts. No crew. No editing. Done before you land home.
Learn how →sciences articles
Verdel's Q-2DMS aims to bring 2D mass spectrometry to more common hardware
Verdel and Warwick's Q-2DMS method reports up to tenfold more usable data on near-isobaric compounds, aiming to widen access to 2D mass spectrometry.
Antibody developability checks are moving into discovery instead of waiting for development
FairJourney Bio's Maria Gonzalez-Pajuelo says developability has become a much more important consideration during antibody discovery.
Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting
ISPE’s 2026 Annual Meeting chairs explain why AI has no track of its own—and why they expect it to show up across the five tracks, from discovery to governance.
MarketScale
MarketScale helps B2B teams cover events like this and turn them into content their market reads. Want to talk through what that looks like?